Teleflex (NYSE:TFX) subsidiary NeoTract said today that the UK Government selected the UroLift system, intended to treat patients with benign prostatic hyperplasia, as one of seven Accelerated Access Collaborative “Rapid Uptake Products.”
The Wayne, Penn.-based company said that the system will now receive support from the Accelerated Access Collaborative which will increase its use by the UK’s NHS.
The decision to include the device in the list follows its placement last year by NHS England as a recipient of the Innovation and Technology Tariff, which also helped support uptake of the treatment.
“I am very pleased by this news. Having been involved in the initial European randomized clinical trial, the potential benefits of the UroLift System to both patients and the NHS quickly became very clear. What was evident from the beginning was that this is an effective day case procedure that, for the first time, preserves sexual function; we could offer most patients the likely prospect going home catheter-free; and they would experience a rapid improvement in symptoms and a return to normal activity with days rather than weeks as is the case for more standard surgical options. What we have learned in the NHS setting since the first procedures in 2014 is that the UroLift System has hugely helped us to improve the use of our resources. In my own Trust, we have been able to relocate the site of operation from the classical operating theatre to a procedure or minor ops room, and we are able to perform up to six UroLift System procedures on one list. This helps us to release precious capacity and reduce waiting times in other parts of our service,” Frimley Health NHS Foundation Trust’s Dr. Neil Barber, who was the first surgeon to routinely offer the UroLift System on the NHS, said in a prepared statement.
“We are humbled and honored to hear that the UroLift System is one of the seven products that Accelerated Access Collaborative has chosen to support, enabling rapid increase in their uptake. Today’s announcement shows that the Government acknowledges the treatment’s unique clinical benefits and our quality of robust clinical evidence, and increasingly, real world data, gathered from NHS urologists,” Teleflex interventional urology EMEA GM Justin Hall said in a press release.
Last month, Neotract presented results from a number of studies of its UroLift system, touting cost reductions and quality of life improvements.